Using contrast-enhanced ultrasound to diagnose recurrent kidney cancer after treatment
Official title: Multi-Modality Detection of RCC Recurrence Post Ablation
Run by Thomas Jefferson University · NCT05641935 · Data updated 2026-11-12
This study is testing if a special type of ultrasound can better detect kidney cancer that comes back after treatment compared to regular imaging methods like CT and MRI.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 210 (estimated) |
| Sponsor | Thomas Jefferson University Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | November 3, 2022 |
| Main results expected | August 31, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT05641935 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults who have previously undergone cryotherapy or microwave therapy for renal cell carcinoma and have available pre-treatment imaging.
✕Probably not a fit
Patients who are medically unstable, terminally ill, or have known sensitivities to the study's contrast agent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase II trial investigates the effectiveness of contrast-enhanced ultrasound (CEUS) in diagnosing recurrent renal cell carcinoma (RCC) following ablation treatments. The study aims to compare the diagnostic accuracy of CEUS with traditional imaging methods like CT and MRI by evaluating sensitivity, specificity, and predictive values. Additionally, it explores the potential benefits of combining CEUS with pre-treatment imaging and utilizing advanced imaging techniques to enhance detection capabilities. Patients will receive Lumason for CEUS imaging and have their medical records reviewed regularly throughout the study.
Why it matters
Potential benefit: If successful, this study could provide a more accurate and less invasive method for monitoring kidney cancer recurrence, improving patient outcomes.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in enhancing imaging techniques for cancer detection, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Previously received cryotherapy or microwave therapy of RCC * Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy * Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study * Be at least 18 years of age * Be medically stable * If a female of child-bearing age, must have a negative pregnancy test * Have signed Informed Consent to participate in the study Exclusion Criteria: * Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable * Patients with known sensitivities to the components of Lumason
Where it's running
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: John Eisenbrey, PhD
- Email: john.eisenbrey@jefferson.edu
- Phone: 215-503-5188
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Plasma DNA Methylation to Classify Kidney Masses Before Surgery
This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.
-
Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home
This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.
-
Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer
We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.
-
Who’s at high risk after RCC surgery? Real-world clues from French registry
This study looks at real-world data from French RCC patients who had local or high-risk locally advanced disease to see how they do after surgery and how doctors decide on adjuvant treatment.
-
First-in-human test of HH160 in people with advanced solid tumors
HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.
-
Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer
This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.